Muscarinic M4 receptor PAMs disclosed in Suven Life Sciences patent

AI Briefing

• – Suven Life Sciences Ltd. discloses new muscarinic M4 receptor PAMs for treatment of multiple neurological disorders.
• – The new compounds are reported to be useful for pain, sleep disorders, depression, schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s disease treatment.
• – The disclosed compounds are 2-amino-pyrimidine derivatives.